A preliminary trial of lamivudine for chronic hepatitis b infection

New England Journal of Medicine

Volumn 333, Issue 25, 1995, Pages 1657-1661

  Dienstag, Jules L ^a   Perrillo, Robert P ^a   Schiff, Eugene R ^a   Bartholomew, Maria ^a   Vicary, Catherine ^a   Rubin, Marc ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; CREATINE KINASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TRIACYLGLYCEROL LIPASE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO; VIRUS INHIBITION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHRONIC DISEASE; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE;

EID: 0029591574     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199512213332501     Document Type: Article

References (22)

1. Perrillo RP, Schiff ER, Davis GL, A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301
2. Di Bisceglie AM, Fong T-L, Fried MW, A randomized, controlled trial of recombinant α-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88: 1887-1892
3. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-323
4. Lau D, Mostowski H, Hoofnagle JH, Sallie R Nucleoside analogue toxicity and mitochondria. Hepatology 1994; 20: 189A-189A abstract.
5. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 8495-8499
6. Tyrrell DLJ, Fischer K, Savani K, Ian W, Jewell L Treatment of chimpanzees and ducks with lamivudine, 2'3' dideoxy 3' thiacytidine results in a rapid suppression of hepadnaviral DNA in sera. Clin Invest Med 1993; 16: Suppl 4: B77-B77 abstract.
7. Benhamou Y, Dohin E, Lunel-Fabiani F, Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396-397
8. Tyrrell DLJ, Mitchell MC, De Man RA, Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18: 112A-112A abstract.
9. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
10. Perrillo RP Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 1990; 12: 1433-1435
11. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-748
12. Hoofnagle JH, Peters M, Mullen KD, Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325
13. Hoofnagle JH, Hanson RG, Minuk GY, Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984; 86: 150-157
14. Zoulim F, Trepo C Nucleoside analogs in the treatment of chronic viral hepatitis: efficiency and complications. J Hepatol 1994; 21: 142-144
15. Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Beames MP, Hoofnagle JH FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992; 16: 127A-127A abstract.
16. Levine ES, Colacino JM, Bowsher RR, Sallie R, Lewis W FIAU incorporates into DNA from human liver and from human hepatoblastoma cells. Hepatology 1994; 20: 189A-189A abstract.
17. Sallie R, Kleiner D, Richardson F, Mechanisms of FIAU induced hepatotoxicity. Hepatology 1994; 20: 209A-209A abstract.
18. Richardson FC, Engelhardt JA, Bowsher RR Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci U S A 1994; 91: 12003-12007
19. Lewis W, Meyer RR, Simpson JF, Colacino JM, Perrino FW Mammalian DNA polymerases α, β, γ, δ, and ε incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 1994; 33: 14620-14624
20. Cui L, Yoon S, Schinazi RF, Sommadossi J-P Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-d-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555-563
21. Colacino JM, Malcolm SK, Jaskunas SR Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 1994; 38: 1997-2002
22. McKenzie R, Fried MW, Sallie R, Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-1105